Publications by authors named "A A Parkhomenko"
Article Synopsis
- - The study evaluated the effectiveness of patiromer, a drug used to manage high potassium levels (hyperkalemia), in patients with heart failure and chronic kidney disease, especially focusing on its benefits when used alongside RAAS inhibitors.
- - Results showed that patiromer was particularly effective in controlling serum potassium levels in patients with more advanced chronic kidney disease (CKD), without increasing the risk of adverse effects.
- - The research concluded that patiromer allows for safer use of RAAS inhibitors in patients with heart failure, especially those with lower estimated glomerular filtration rates (eGFR), while minimizing hyperkalemia risk.
The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial.
View Article and Find Full Text PDFArticle Synopsis
- * The study involved over 18,000 patients who were randomly assigned to receive either CSL112 or a placebo, showing that CSL112 resulted in a numerical decrease in rates of cardiovascular death and recurrent MIs over 1 year.
- * While CSL112 did not significantly meet the primary endpoint goals, the results suggest it may help reduce the risk of heart-related complications, indicating a potential benefit of apoA-I in managing cholesterol and plaque stability in at-risk patients.
Article Synopsis
- Empagliflozin, a medication tested in the EMPACT-MI trial, showed promise in reducing heart failure (HF) hospitalizations but did not impact overall mortality when administered within two weeks post-acute myocardial infarction (AMI).
- In the study of over 6,500 patients, worsening left ventricular ejection fraction (LVEF) and congestion significantly increased the risk of death and HF hospitalizations.
- The drug effectively lowered the risk for HF hospitalizations regardless of the patients' LVEF status or congestion, and its safety profile remained consistent across different patient groups.
Background: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear.
View Article and Find Full Text PDF